Transient pharmacologic lowering of A production prior to deposition results in sustained reduction of amyloid plaque pathology

Molecular Neurodegeneration

Volumn 7, Issue 1, 2012, Pages

  Das, Pritam ^a   Verbeeck, Christophe ^a   Minter, Lisa ^b   Chakrabarty, Paramita ^c   Felsenstein, Kevin ^c   Kukar, Thomas ^d   Maharvi, Ghulam ^a   Fauq, Abdul ^a   Osborne, Barbara A ^b   Golde, Todd E ^c  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

secretase inhibition; A; Alzheimers disease; APP; Therapeutics

Indexed keywords

AMYLOID BETA PROTEIN; GAMMA SECRETASE INHIBITOR; LY 411 575; UNCLASSIFIED DRUG;

AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; IMMUNOHISTOLOGY; IMMUNOPHENOTYPING; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; SINGLE DRUG DOSE; WESTERN BLOTTING;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, TRANSGENIC; PLAQUE, AMYLOID;

MUS;

EID: 84864917736     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-7-39     Document Type: Article

References (17)

1. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Jack CR Jr, et al. Lancet Neurol 2010 9 1 119 128 10.1016/S1474- 4422(09)70299-6 20083042
2. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Hardy J, Selkoe DJ, Science 2002 297 5580 353 356 10.1126/science.1072994 12130773
3. Revising the definition of Alzheimer's disease: a new lexicon. Dubois B, et al. Lancet Neurol 2010 9 11 1118 1127 10.1016/S1474-4422(10)70223-4 20934914
4. Targeting Abeta and tau in Alzheimer's disease, an early interim report. Golde TE, Petrucelli L, Lewis J, Exp Neurol 2010 223 2 252 266 10.1016/j.expneurol.2009.07.035 19716367
5. gamma-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes. Imbimbo BP, Giardina GA, Curr Top Med Chem 2011 11 12 1555 1570 10.2174/156802611795860942 21510832
6. Anti-abeta therapeutics in Alzheimer's disease: the need for a paradigm shift. Golde TE, Schneider LS, Koo EH, Neuron 2011 69 2 203 213 10.1016/j.neuron.2011.01.002 21262461
7. Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition. Das P, et al. Neurobiol Aging 2001 22 5 721 727 10.1016/S0197-4580(01)00245-7 11705631
8. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition. Abramowski D, et al. J Pharmacol Exp Ther 2008 327 2 411 424 10.1124/jpet.108.140327 18687920
9. Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. Levites Y, et al. J Clin Invest 2006 116 1 193 201 16341263
10. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Jarrett JT, Lansbury PT Jr, Cell 1993 73 6 1055 1058 10.1016/0092-8674(93)90635-4 8513491
11. Age-Dependent Changes in Brain, CSF, and Plasma Amyloid Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease. Kawarabayashi T, et al. J Neurosci 2001 21 372 381 11160418
12. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in the brain. Dovey H, Varghese J, Anderson JP, J Neurochem 2000 76 1 10
13. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. Wong GT, et al. J Biol Chem 2004 279 13 12876 12882 14709552
14. Suppression of amyloid deposition leads to long-term reductions in Alzheimer's pathologies in Tg2576 mice. Karlnoski RA, et al. J Neurosci 2009 29 15 4964 4971 10.1523/JNEUROSCI.4560-08.2009 19369565
15. A multigram chemical synthesis of the gamma-secretase inhibitor LY411575 and its diastereoisomers. Fauq AH, et al. Bioorg Med Chem Lett 2007 17 22 6392 6395 10.1016/j.bmcl.2007.07.062 17897827
16. Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. Chakrabarty P, et al. FASEB J 2010 24 2 548 559 10.1096/fj.09-141754 19825975
17. IFN-gamma promotes complement expression and attenuates amyloid plaque deposition in amyloid beta precursor protein transgenic mice. Chakrabarty P, et al. J Immunol 2010 184 9 5333 5343 10.4049/jimmunol.0903382 20368278